Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults

Vaccine

Volumn 19, Issue 7-8, 2000, Pages 886-894

  Kroon, Frank P ^a   Van Dissel, Jaap T ^a   Ravensbergen, Elisabeth ^a   Nibbering, Peter H ^a   Van Furth, Ralph ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AIDS; CD4+ T lymphocytes; HIV infection; Immunization; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine

Indexed keywords

CD4 ANTIGEN; PNEUMOCOCCUS POLYSACCHARIDE; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 0034703851     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00232-2     Document Type: Article

References (49)

1. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a Pneumococcal vaccine failure
2. Unusual manifestations of Pneumococcal infection in human immunodeficiency virus-infected individuals: the past revisited
3. The role of human immunodeficiency virus infection in Pneumococcal bacteremia in San Francisco residents
4. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus
5. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspective
6. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sexworkers in Nairobi, Kenya
7. Bacterial pneumoniae in persons infected with the human immunodeficiency virus
8. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection
9. Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP)
10. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis
11. Bacterial pneumoniae in HIV
12. Should patients positive for HIV receive pneumococcal vaccine?
13. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: five years follow-up of antibody concentrations
14. Abnormal antibody responses in patients with persistent lymphadenopathy
15. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients
16. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy
17. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with the human immunodeficiency virus type 1
18. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection
19. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients
20. Response to vaccination with Pneumovax(TM) in HIV infected patients
21. Response to Pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus
22. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent Pneumococcal vaccine
23. Defective IgG2 response to Pneumovax in HIV seropositive patients
24. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination
25. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response
26. Infant B cell responses to polysaccharide determinants
27. Thymus-independent and thymus-dependent responses to polysaccharide antigens
28. T cell-independent antigens type 2
29. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes
30. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants
31. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
32. Effect of immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial
33. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease
34. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus
35. Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus
36. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection
37. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children
38. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults
39. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease
40. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines
41. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens
42. Booster response to polysaccharide vaccine at 14 months after immunization with tetravalent pneumococcal conjugate vaccine in infancy is dose dependent
43. Response at 24 months to a booster dose of pneumococcal polysaccharide vaccine in children immunized with pentavalent pneumococcal conjugate vaccine (PncCRM) in infancy
44. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children
45. Avidity of IgG antibodies for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines
46. Safety of revaccination with pneumococcal polysaccharide vaccine
47. Opsonic activity and concentration of antibodies to Streptococcus pneumoniae type 6B polysaccharide